Histone Deacetylase Inhibitors Market is expected to grow at a CAGR of xx% during 2021 to 2027. Histone deacetylase inhibitors are the products involved in inhibition of histone deacetylase, which removes acetyl groups from N-acetyl lysine amino acid present on the histone, and allows the histones to wrap DNA more tightly. Histone deacetylase inhibitors are used in the neurology and psychiatry as anti-epileptics and mood stabilizers. Moreover, these are also used in the treatment of cancer, parasitic, and inflammatory diseases. Histone deacetylase (HDAC) is an enzyme that inhibits histone deacetylase by eliminating the scetyl group from the amino acid n-acetyl lysine. Histone deacetylase inhibitors are showing promise as a tool for cancer diagnosis, treatment, and prognosis. It’s also used to treat haematological malignancies and plays a vital function in epigenetic and non-epigenetic regulation. Because of the rising incidence of various types of cancer and the growing need for improved cancer detection and therapies, the global histone deacetylase inhibitors market is booming. Furthermore, one of the primary drivers of market expansion is an increase in R&D activities for cancer therapy and other neurological disorders. However, restrictive reimbursement regulations and HDAC inhibitor uncertainty may limit market expansion to some extent. Several histone deacetylase inhibitor compounds have been tested in clinical trials for various cancers in recent years. The chemical structure of these inhibitors is used to classify them. Hydroxamic acid-based drugs are the most extensively studied class of histone deacetylase inhibitors.